Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H. Klotz L, et al. Sci Transl Med. 2019 May 1;11(490):eaao5563. doi: 10.1126/scitranslmed.aao5563. Sci Transl Med. 2019. PMID: 31043571 Clinical Trial.
Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis.
Thiele Née Schrewe L, Guse K, Tietz S, Remlinger J, Demir S, Pedreiturria X, Hoepner R, Salmen A, Pistor M, Turner T, Engelhardt B, Hermann DM, Lühder F, Wiese S, Chan A. Thiele Née Schrewe L, et al. J Neuroinflammation. 2020 Jan 8;17(1):9. doi: 10.1186/s12974-019-1677-z. J Neuroinflammation. 2020. PMID: 31915017 Free PMC article.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis.
Gruber RC, Wirak GS, Blazier AS, Lee L, Dufault MR, Hagan N, Chretien N, LaMorte M, Hammond TR, Cheong A, Ryan SK, Macklin A, Zhang M, Pande N, Havari E, Turner TJ, Chomyk A, Christie E, Trapp BD, Ofengeim D. Gruber RC, et al. Among authors: turner tj. Nat Commun. 2024 Nov 22;15(1):10116. doi: 10.1038/s41467-024-54430-8. Nat Commun. 2024. PMID: 39578444 Free PMC article.
Bruton tyrosine kinase inhibitors for multiple sclerosis.
Krämer J, Bar-Or A, Turner TJ, Wiendl H. Krämer J, et al. Among authors: turner tj. Nat Rev Neurol. 2023 May;19(5):289-304. doi: 10.1038/s41582-023-00800-7. Epub 2023 Apr 13. Nat Rev Neurol. 2023. PMID: 37055617 Free PMC article. Review.
71 results